Want to see OBX full AI Analyst Report?
Top Page
Obsidian Therapeutics
(NASDAQ:OBX)
Select Model
Select Model
Rating:48Neutral
Price Target:
$17.50
▼(-7.89% Downside)
Action:Reiterated
Date:08/17/26
The score is driven primarily by financial fundamentals: despite a significantly improved balance sheet (no debt, positive equity) and reduced operating losses, OBX remains pre-revenue with ongoing cash burn and earnings that do not appear to translate into operating cash flow. Technicals add a modest headwind due to weak near-term trend signals, while valuation looks cheap on P/E but is discounted for likely non-recurring earnings quality.
Positive Factors
Debt Elimination
Eliminating debt materially reduces solvency risk, interest burden and refinancing pressure. This gives the company greater financial flexibility while it develops its pipeline, although its modest asset base still limits the overall cushion.
Negative Factors
No Operating Revenue
The absence of revenue means the business has not yet demonstrated commercial demand or self-sustaining operations. Future progress therefore depends on successful development, regulatory advancement and eventual monetization of its therapeutic programs.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt Elimination
Eliminating debt materially reduces solvency risk, interest burden and refinancing pressure. This gives the company greater financial flexibility while it develops its pipeline, although its modest asset base still limits the overall cushion.
Read all positive factors
Obsidian Therapeutics (OBX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.05B
Dividend YieldN/A
Average Volume (3M)476.74K
Price to Earnings (P/E)<0.1
Beta (1Y)2.65
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees87
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding61,772,877
10 Day Avg. Volume1,033,441
30 Day Avg. Volume476,735
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.33
Price to Sales (P/S)0.00
P/FCF Ratio-0.36
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$40.00Price Target Upside110.53% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Obsidian Therapeutics Business Overview & Revenue Model
Company Description
A clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor-infiltrating lymphocyte (TIL) cell therapies for the treatment of patients with solid tumors. Its proprietary cytoDRiVE® technolo...
How the Company Makes Money
null...
Obsidian Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
72
Positive
Cash Flow
22
Negative
| Breakdown |
|---|
Income Statement |
| Total Revenue |
| Gross Profit |
| EBITDA |
| Net Income |
Balance Sheet |
| Total Assets |
| Cash, Cash Equivalents and Short-Term Investments |
| Total Debt |
| Total Liabilities |
| Stockholders Equity |
Cash Flow |
| Free Cash Flow |
| Operating Cash Flow |
| Investing Cash Flow |
| Financing Cash Flow |
Obsidian Therapeutics Technical Analysis
Negative
19.00
Price Trends
19.31
Negative
19.02
Negative
13.48
Positive
Market Momentum
-0.82
Positive
38.49
Neutral
8.07
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OBX, the sentiment is Negative. The current price of 19 is above the 20-day moving average (MA) of 17.33, below the 50-day MA of 19.31, and above the 200-day MA of 13.48, indicating a neutral trend. The MACD of -0.82 indicates Positive momentum. The RSI at 38.49 is Neutral, neither overbought nor oversold. The STOCH value of 8.07 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for OBX.
Obsidian Therapeutics Risk Analysis
Obsidian Therapeutics disclosed 47 risk factors in its most recent earnings report. Obsidian Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Obsidian Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $15.93M | -0.44 | -218.59% | ― | ― | 38.14% | |
49 Neutral | $34.16M | -0.31 | 411.46% | ― | -51.03% | -35.20% | |
48 Neutral | $1.05B | 0.05 | -210.64% | ― | ― | ― | |
45 Neutral | $12.96M | -0.07 | -443.08% | ― | ― | 75.09% | |
43 Neutral | $20.34M | -2.58 | -56.96% | ― | -56.64% | 64.88% | |
41 Neutral | $8.67M | -0.26 | -223.19% | ― | -42.74% | 20.66% |
* Healthcare Sector Average
OBX
Obsidian Therapeutics
13.41
9.81
272.50%
GTBP
GT Biopharma
6.83
-12.19
-64.10%
MRKR
Marker Therapeutics
1.19
0.31
35.07%
PASG
Passage Bio
4.80
-2.88
-37.50%
CELU
Celularity
1.32
-0.72
-35.29%
LGVN
Longeveron
2.91
-5.03
-63.33%
Obsidian Therapeutics Corporate Events
Executive/Board ChangesDelistings and Listing ChangesM&A TransactionsRegulatory Filings and Compliance
Obsidian Therapeutics Completes Merger and Leadership Transition
Neutral
Aug 4, 2026
Following the completion of mergers on August 3, 2026, Gazelle Parent, Inc. was renamed Obsidian Therapeutics, Inc., with Legacy Obsidian holders owning about 51.6% and PIPE investors 47.2% of the fully diluted common stock. Galera Common Stock is...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.